A Phase 2 interventional study of VGT-309 in Lung Cancer, sponsored by Vergent Bioscience, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-17.
Sponsored by Vergent Bioscience, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.
Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 1,027th largest by enrollment of the 1,908 interventional ones that give a count, is one of 119 that started in 2022, is one of 633 in phase 2, and was the 1,981st registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–77 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
Roswell Park Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,462 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 660 · Phase 2 866 · Phase 3 179 · Phase 4 21
First in 1990; this study’s year is marked. 119 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 48 across the 1,908 interventional studies, 123 across the 442 observational. Of the 1,674 that completed or were terminated, 583 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
620 of 2,462 have an industry lead sponsor. The 10 most frequent:
Vergent Bioscience, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Vergent Bioscience, Inc. has 3 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
243 of the studies in Lung Neoplasms with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07499674Phase 3Vergent Bioscience, Inc.Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
Add all 243 to your calendar (.ics) → With an account.
Among the 2,462 studies in Lung Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.
A Phase 2, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer in subjects undergoing lung cancer surgery. A total of 40 subjects will be enrolled to ensure at least 38 evaluable subjects with the option to expand enrollment by protocol amendment if deemed necessary to meet primary and/or secondary objectives.
Following agreement with and signing of the informed consent, subjects will undergo screening measurements for the study. Assessments include the following, unless they have been done within 4 weeks prior to the anticipated dosing:
Following clearance of all enrollment criteria, each subject will receive an IV administration of 0.32 mg/kg VGT-309 at 12-36 hours prior to surgery (refer to section VGT-309 Dosing, below). Upon dosing, subjects will be observed for up to 2 hours and asked about possible treatment emergent adverse events.
Subjects will undergo surgical resection as planned and within the time specified following VGT-309 dosing. Measurements of efficacy will be taken during surgery and during the pathological examination of all surgical specimens.
Following surgery, subjects will be monitored for safety during their hospitalization. After discharge from the hospital, and approximately 14 days post-surgery, the subjects will be contacted by telephone to assess their well-being. Between 19 to 39 days post-surgery, subjects will either return to the clinic or participate in a telehealth visit for final safety assessments. If there are no adverse events requiring further follow up, subjects will then be released from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Be male or female and meet the following conditions:
Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:
They are required to maintain abstinence from screening through Day 30.
Have acceptable kidney and liver functions at study entry as evidenced by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm in an open label study
Drug: VGT-309
VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
Clinically Significant Event (CSE)
Identification of the proportion of subjects with at least one CSE as defined by: A. Localization of a Pulmonary Nodule using VGT-309 near-infrared (NIR) Imaging when white light and palpation failed to identify a nodule. B. Synchronous Lesion Identification using VGT-309 NIR Imaging when not identified by white light and palpation. C. Positive Margin Identification with only VGT-309 NIR Imaging when deemed negative by the surgeon by white light and palpation.
Time frame: Day of surgery
Sensitivity
Sensitivity is defined as the probability that tissue fluoresces intraoperatively when it is cancer as confirmed by histology. Sensitivity = (True Positive)/(True Positive + False Negative)
Time frame: Day of surgery
Negative Predictive Value
Negative predictive value is defined as the probability that a tissue sample does not contain cancer on histologic exam if it does not fluoresce intraoperatively. Negative Predictive Value = (True Negative)/(True Negative + False Negative)
Time frame: Day of surgery
Specificity
Specificity is defined as the probability that tissue does not fluoresce intraoperatively when it is not cancerous as confirmed by histology. Specificity = (True Negative)/(True Negative + False Positive)
Time frame: Day of surgery
Positive Predictive Value
Positive predictive value is defined as the probability that a tissue sample contains cancer on histologic exam if it fluoresces intraoperatively. Positive Predictive Value = (True Positive)/(True Positive + False Positive)
Time frame: Day of surgery
| Milestone | VGT-309 |
|---|---|
| Started | 40 |
| Dosing | 40 |
| Surgery | 40 |
| Completed | 40 |
| Not completed | 0 |
Identification of the proportion of subjects with at least one CSE as defined by: A. Localization of a Pulmonary Nodule using VGT-309 near-infrared (NIR) Imaging when white light and palpation failed to identify a nodule. B. Synchronous Lesion Identification using VGT-309 NIR Imaging when not identified by white light and palpation. C. Positive Margin Identification with only VGT-309 NIR Imaging when deemed negative by the surgeon by white light and palpation.
| Proportion of subjects | VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery |
|---|---|
| Clinically Significant Event (CSE) | 0.425 (0.270 to 0.591) |
Sensitivity is defined as the probability that tissue fluoresces intraoperatively when it is cancer as confirmed by histology. Sensitivity = (True Positive)/(True Positive + False Negative)
| Proportion of lesions | VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery |
|---|---|
| Sensitivity | 0.850 (0.675 to 0.939) |
Negative predictive value is defined as the probability that a tissue sample does not contain cancer on histologic exam if it does not fluoresce intraoperatively. Negative Predictive Value = (True Negative)/(True Negative + False Negative)
| Proportion of lesions | VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery |
|---|---|
| Negative Predictive Value | 0.455 (0.202 to 0.733) |
Specificity is defined as the probability that tissue does not fluoresce intraoperatively when it is not cancerous as confirmed by histology. Specificity = (True Negative)/(True Negative + False Positive)
| Proportion of lesions | VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery |
|---|---|
| Specificity | 0.333 (0.126 to 0.633) |
Positive predictive value is defined as the probability that a tissue sample contains cancer on histologic exam if it fluoresces intraoperatively. Positive Predictive Value = (True Positive)/(True Positive + False Positive)
| Proportion of lesions | VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery |
|---|---|
| Positive Predictive Value | 0.773 (0.650 to 0.862) |
Collected over Adverse events were collected from the time of dosing through completion of the End-of-Study Visit (Days 22-36). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VGT-309 0.32mg/kg | 0/40 (0%) | 8/40 (20%) | 40/40 (100%) |
| Event | VGT-309 0.32mg/kg |
|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 3/40 |
| IleusGastrointestinal disorders | 1/40 |
| VomitingGastrointestinal disorders | 1/40 |
| HypervolaemiaMetabolism and nutrition disorders | 1/40 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/40 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/40 |
| Traumatic haemothoraxInjury, poisoning and procedural complications | 1/40 |
| Event | VGT-309 0.32mg/kg |
|---|---|
| Procedural painInjury, poisoning and procedural complications | 40/40 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 25/40 |
| HypotensionVascular disorders | 17/40 |
| NauseaGastrointestinal disorders | 9/40 |
| Urinary retentionRenal and urinary disorders | 7/40 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/40 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 6/40 |
| Sinus bradycardiaCardiac disorders | 6/40 |
| VomitingGastrointestinal disorders | 5/40 |
| HypomagnesaemiaMetabolism and nutrition disorders | 5/40 |
One-time dose by IV infusion over 15-20 minutes using a syringe pump between 12-36 hours prior to the start of surgery
| Age, Categorical(Participants) | VGT-309 0.32mg/kg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 13 |
| >=65 years | 27 |
| Age, Customized(years) | VGT-309 0.32mg/kg |
|---|---|
| Age | 66 ± 10.51 |
| Sex: Female, Male(Participants) | VGT-309 0.32mg/kg |
|---|---|
| Female | 28 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | VGT-309 0.32mg/kg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 39 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | VGT-309 0.32mg/kg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 29 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Region of Enrollment(participants) | VGT-309 0.32mg/kg |
|---|---|
| United States | 40 |
| Height(cm) | VGT-309 0.32mg/kg |
|---|---|
| Mean | 165.33 ± 13.863 |
| Weight(kg) | VGT-309 0.32mg/kg |
|---|---|
| Mean | 77.61 ± 23.658 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Jun 2023, 13 months.
Results were first posted in Oct 2024, 1 year 3 months after primary completion.
Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 13 months is below that.
Counting every sponsor, half of 362 studies reached it within 65 months; a quarter within 34 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cathepsin-targeted Fluorescent Imaging Probe VGT-309
Vergent Bioscience, Inc.